Marinova Pty Ltd., 249 Kennedy Drive, Cambridge, TAS 7170, Australia.
Mar Drugs. 2020 Dec 24;19(1):4. doi: 10.3390/md19010004.
Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections-including the current pandemic strain SARS-CoV-2-that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.
肺功能受损是感染性和非感染性疾病的共同特征。影响肺功能的病毒感染——包括当前的 SARS-CoV-2 大流行株——可导致急性和长期慢性损害。SARS-CoV-2 感染会抑制先天免疫并促进炎症反应。由于大流行影响了更多人群，针对 SARS-CoV-2 的这些方面非常重要。在临床和动物研究中，褐藻胶已被证明可增强先天免疫并减少炎症。此外，饮食褐藻胶已被证明可减轻急性病毒感染模型中的肺损伤。已经描述了体外直接抑制 SARS-CoV-2，但并非普遍现象。这篇简短的综述总结了目前关于褐藻胶在病毒性肺感染和肺损伤方面的研究。
